EE200200545A - Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine - Google Patents

Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine

Info

Publication number
EE200200545A
EE200200545A EEP200200545A EEP200200545A EE200200545A EE 200200545 A EE200200545 A EE 200200545A EE P200200545 A EEP200200545 A EE P200200545A EE P200200545 A EEP200200545 A EE P200200545A EE 200200545 A EE200200545 A EE 200200545A
Authority
EE
Estonia
Prior art keywords
cabergoline
solvate
obtaining
preparation
crystalline form
Prior art date
Application number
EEP200200545A
Other languages
English (en)
Inventor
Tomasi Attilio
Magenes Stefania
Ungari Mario
Ramella Giuliano
Pallanza Gianfranco
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200545(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Publication of EE200200545A publication Critical patent/EE200200545A/et
Publication of EE05088B1 publication Critical patent/EE05088B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200200545A 2000-03-24 2001-03-19 Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine EE05088B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (2)

Publication Number Publication Date
EE200200545A true EE200200545A (et) 2004-04-15
EE05088B1 EE05088B1 (et) 2008-10-15

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200545A EE05088B1 (et) 2000-03-24 2001-03-19 Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine

Country Status (31)

Country Link
US (2) US6727363B2 (et)
EP (1) EP1272489B1 (et)
JP (1) JP4184666B2 (et)
KR (1) KR100827558B1 (et)
CN (1) CN1188412C (et)
AR (1) AR032449A1 (et)
AT (1) ATE250601T1 (et)
AU (2) AU780747B2 (et)
BR (1) BR0109507A (et)
CA (1) CA2402836A1 (et)
CZ (1) CZ20023176A3 (et)
DE (1) DE60100858T2 (et)
DK (1) DK1272489T3 (et)
EA (1) EA005928B1 (et)
EE (1) EE05088B1 (et)
ES (1) ES2208602T3 (et)
GB (1) GB0007308D0 (et)
HK (1) HK1052348B (et)
HU (1) HUP0300591A3 (et)
IL (2) IL150985A0 (et)
MX (1) MXPA02009283A (et)
MY (1) MY134189A (et)
NO (1) NO20024321D0 (et)
NZ (1) NZ521316A (et)
PE (1) PE20011140A1 (et)
PL (1) PL358253A1 (et)
PT (1) PT1272489E (et)
SI (1) SI1272489T1 (et)
SK (1) SK13582002A3 (et)
WO (1) WO2001070740A1 (et)
ZA (1) ZA200206045B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
EP1485383A1 (en) * 2002-03-15 2004-12-15 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
KR100605794B1 (ko) * 2002-03-15 2006-08-01 파마시아 코포레이션 카베르골린의 제1형 결정을 제조하는 방법
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
CA2525104A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
EP2185169A2 (en) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
EP0664705B1 (en) 1993-08-18 2000-10-04 Alcon Laboratories, Inc. Compositions of ergoline derivatives for the treatment of glaucoma
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
US6114326A (en) 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline

Also Published As

Publication number Publication date
PE20011140A1 (es) 2001-11-01
PL358253A1 (en) 2004-08-09
EA200201016A1 (ru) 2003-02-27
HUP0300591A2 (hu) 2003-07-28
EP1272489B1 (en) 2003-09-24
JP4184666B2 (ja) 2008-11-19
MXPA02009283A (es) 2003-03-12
AR032449A1 (es) 2003-11-12
NO20024321L (no) 2002-09-10
HK1052348B (zh) 2005-09-16
CN1419554A (zh) 2003-05-21
ZA200206045B (en) 2003-07-29
GB0007308D0 (en) 2000-05-17
IL150985A (en) 2007-03-08
US20030149067A1 (en) 2003-08-07
AU2005203071A1 (en) 2005-08-11
NO20024321D0 (no) 2002-09-10
HK1052348A1 (en) 2003-09-11
CN1188412C (zh) 2005-02-09
EA005928B1 (ru) 2005-08-25
AU780747B2 (en) 2005-04-14
DE60100858T2 (de) 2004-07-29
KR100827558B1 (ko) 2008-05-07
MY134189A (en) 2007-11-30
EP1272489A1 (en) 2003-01-08
NZ521316A (en) 2004-05-28
AU2005203071B2 (en) 2007-10-18
IL150985A0 (en) 2003-02-12
EE05088B1 (et) 2008-10-15
ATE250601T1 (de) 2003-10-15
DE60100858D1 (de) 2003-10-30
ES2208602T3 (es) 2004-06-16
CZ20023176A3 (cs) 2003-02-12
JP2003528100A (ja) 2003-09-24
KR20020081587A (ko) 2002-10-28
HUP0300591A3 (en) 2009-01-28
US6727363B2 (en) 2004-04-27
SI1272489T1 (en) 2004-02-29
US6953854B2 (en) 2005-10-11
SK13582002A3 (sk) 2003-04-01
PT1272489E (pt) 2004-02-27
AU6211001A (en) 2001-10-03
WO2001070740A1 (en) 2001-09-27
US20040092744A1 (en) 2004-05-13
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
DK1272489T3 (da) 2003-12-15

Similar Documents

Publication Publication Date Title
EE200200545A (et) Meetod kabergoliini kristallvormi I saamiseks, kabergoliini solvaat ning selle valmistamine
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
IL155306A0 (en) Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
HK1052183A1 (zh) 製造tetrahydrobenzothiepines的方法
IL151059A0 (en) Method for the preparation of citalopram
HK1068069A1 (en) Method for the preparation of intermediate of citalopram
IL151339A0 (en) Method for the preparation of citalopram
AU2001251083A1 (en) Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
GB0007307D0 (en) Crystalline form || of cabergoline
IL151467A0 (en) Method for the preparation of citalopram
GB0007309D0 (en) Crystalline form V|| of cabergoline
HK1056171A1 (en) Method for the preparation of citalopram
IL151490A0 (en) Method for the preparation of citalopram
IL148525A0 (en) Method for the preparation of citalopram
PL346034A1 (en) Method of obtaining substituted banzoylcyanide aminohydrazones
IL151489A0 (en) Method for the preparation of citalopram
ITMI20000680A0 (it) Ciclopentadieni sostituiti policiclici e metodo per la loro preparazione
PL347056A1 (en) Novel compounds of heterocycloalkylbezocyclobutane and heterocycloarylbenzocyclobutane, method of obtaining them and pharmacological compositions containming such compounds
EE05218B1 (et) Meetod distamtsiini derivaadi valmistamiseks
PL347407A1 (en) Method of obtaining derivatives of 5,6,7,8-tetrahydronaphtalen-2-ole
PL341634A1 (en) Method of obtaining derivatives of phenylsulphonylmethyltetrazole
SI1265882T1 (en) Method for the preparation of citalopram
PL339713A1 (en) Method of obtaining triallylmethylamines

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100319